Skip to main content
. Author manuscript; available in PMC: 2011 Jan 10.
Published in final edited form as: Oncogene. 2010 May 24;29(28):4068–4079. doi: 10.1038/onc.2010.177

Figure 2.

Figure 2

PAT1 and PAT4 are both required for normal proliferation of MCF-7 breast cancer cells. The proliferation of MCF-7 breast cancer cells after transfection with siRNAs for mTOR (si825, si826 and si827; A), PAT1 (si158, si159 and si160; B) and PAT4 (si435, si436 and si437; C) was compared to control cells treated with a scrambled siRNA control (sc), lipofectamine™ only (lp) and non-transfected (nt). A combination of the most effective PAT1 and PAT4 siRNAs did not reduce cell number further (B). Bar chart (D) shows cell number at 120 h for samples treated with the most effective siRNAs for mTOR (si827), PAT1 (si159) and PAT4 (si437) normalised to lp control. Error bars represent SEM. *P<0.0002: reduced versus lp control. All measurements were made on triplicate samples and the experiment was repeated three times with similar results.